Trump blames "global freeloading" for costly United States drugs. That's not the problem

Trump blames

Trump blames "global freeloading" for costly United States drugs. That's not the problem

Unveiled! President Donald Trump's long-awaited plan to bring down drug prices, unveiled today, will mostly spare the pharmaceutical industry he previously accused of "getting away with murder" and instead focus on increasing private competition and requiring more openness about costs. "Everyone involved in the broken system - the drug makers, insurance companies, distributors, pharmacy benefit managers, and many others - contribute to the problem".

Trump said his administration would take aim at the "middlemen" in the drug industry who became "very, very rich", an apparent reference to health insurers and pharmacy benefit managers. It comes after more than a year of promises to tackle pharmacy costs that are squeezing millions of Americans.

Rea said any proposals that the administration can do itself are more likely to happen than those that need congressional approval. HHS has 50 actions planned or under consideration, which can be done through administrative and executive action, Azar said, adding that it will likely take months to roll out numerous policies.

Along with the speech will be an outline of what the administration plans to do about them, as well as highlighting budget proposals that would make changes to how drugs are paid for under Medicare, which insures Americans who are 65 and older. "In some cases, medications that cost a few dollars in a foreign country cost hundreds of dollars in America", Trump said. "It's time to end global freeloading once and for all".

Trump also placed blame on foreign governments, saying they extort unreasonably low prices from USA drugmakers, forcing companies to charge more in this country. "We do subsidize the world because we support the profits of pharmaceutical companies".

Trump's Plan Includes Plenty of Steps He Can Take Without Congress: "It's framed as a pro-competitive agenda, and touches on a range of government programs that the administration can change through regulation - so that the president can take unilateral action", Daniel N. Mendelson, the president of research consultancy Avalere Health, told The New York Times.

"We are outraged that he has chosen to side with the powerful multinational pharmaceutical corporations and against American retirees and consumers", Fiesta said. According to statistics of the Organization for Economic Co-operation and Development, the United States has the highest annual health expenditures of any industrialized country, at almost $10,000 per capita, with drugs prices playing a major role.

"Everyone in the system is wetting their beak along the way", Azar said. While overall drug spending has slowed over the past two years, it still makes up a large share of healthcare expenditures, about 10% in 2016, fueled by the rising price of specialty drugs.

The blueprint echoes some of those initiatives and says curbing abuse of FDA's Risk Evaluation and Mitigation Strategy (REMS) programs will be a priority to help generic drugs come to market faster. The rule should be that only those drugs that haven't increased their list price for 18 months get to be in a protected class. "They're taking it from both sides, getting compensated from insurance companies and from the drug companies they've negotiating against", he said. "But generally they have gone along with it", said Shondelmeyer. The plan is created to provide positive changes and consumer relief with respect to the price of pharmaceuticals.

But h ere's a list of some of the proposals that would appear to have a direct effect on issuers of Medicare Advantage plans, Medicare Part D drug plans or commercial health plans. Importantly, this strategic direction will move the Food and Drug Administration down its current path of trying to increase competition by paving the way for more approvals of generics, biosimilars and biologics, Klasmeier added. "[There are already] some incentives in Medicare Part D drug plans to encourage drug companies to keep their prices low".

By the numbers, the average person in the USA pays about $1,000 a year for prescription drugs.

"We have got to negotiate drug prices with Medicare".

"It's hard to know why Germany or France of Australia would agree to something like that", said Professor Jack Hoadley of Georgetown University's Health Policy Institute. A drug maker will negotiate with the entity paying for the drug, which, in the USA, is often a pharmacy benefits manager, such as Express Scripts, or a health plan administered by a business or a union.

Related news